Company / Working Capital
Aurinia Pharmaceuticals Inc. Working Capital History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$398.2M
FY2025
5-year range
$347.6M / $472.7M
FY2021-FY2025
Trend
+14.2%
vs FY2024
Sector context
#108 of 213
Health Care
What the data says
At $398M, Aurinia Pharmaceuticals Inc.'s working capital ranks #108 of 213 in the Health Care sector. Improved from $348M to $398M over the past 2 years.
Based on SEC 10-K filings.
$398M in FY2025 with a 5-year CAGR of +0.6%.
Improved from $348M to $398M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +0.2%
- 5-Year CAGR
- +0.6%
- 10-Year CAGR
- -
Sector benchmark
#108 of 213 in Health CareTop 51% of 213This company $398.2M Sector average $934.6M
▼
-57.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +0.6%, indicating consistent growth.
- In FY2025, working capital increased 14.2% year-over-year.
- Ranks #108 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2021.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $398.2M | +14.2% |
| FY2024 | $348.8M | +0.4% |
| FY2023 | $347.6M | -12.3% |
| FY2022 | $396.4M | -16.1% |
| FY2021 | $472.7M | +22.0% |
| FY2020 | $387.4M | +27.5% |
| FY2019 | $303.8M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026